Combined effect of CCR5-Δ32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission

Journal of Virology

Volumn 79, Issue 18, 2005, Pages 11677-11684

  Hladik, Florian ^a   Liu, Huanliang ^a,c   Speelmon, Emily ^a   Livingston Rosanoff, Devon ^a   Wilson, Sean ^a   Sakchalathorn, Polachai ^a   Hwangbo, Yon ^a   Greene, Benjamin ^a   Zhu, Tuofu ^a   McElrath, M Juliana ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4;

ADULT; ALLELE; ARTICLE; CAUCASIAN; CELL TYPE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; EMBRYO; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HELPER CELL; HETEROZYGOSITY; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OPEN READING FRAME; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

BASE SEQUENCE; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; DNA; GENE EXPRESSION; HETEROZYGOTE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; MALE; MONOCYTES; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECEPTORS, CCR5; RISK-TAKING;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 24644465001     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.18.11677-11684.2005     Document Type: Article

References (61)

1. + cells. J. Virol. 78:2277-2287.
2. Benkirane, M., D. Y. Jin, R. F. Chun, R. A. Koup, and K. T. Jeang. 1997. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J. Biol. Chem. 272:30603-30606.
3. Cann, A. J., J. A. Zack, A. S. Go, S. J. Arrigo, Y. Koyanagi, P. L. Green, S. Pang, and I. S. Y. Chen. 1990. Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. J. Virol. 64:4735-4742.
4. Clegg, A. O., L. J. Ashton, R. A. Biti, P. Badhwar, P. Williamson, J. M. Kaldor, G. J. Stewart et al. 2000. CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. AIDS 14:103-108.
5. Cohen, O. J., M. Vaccarezza, G. K. Lam, B. F. Baird, K. Wildt, P. M. Murphy, P. A. Zimmerman, T. B. Nutman, C. H. Fox, S. Hoover, J. Adelsberger, M. Baseler, J. Arthos, R. T. Davey, Jr., R. L. Dewar, J. Metcalf, D. J. Schwartzentruber, J. M. Orenstein, S. Buchbinder, A. J. Saah, R. Detels, J. Phair, C. Rinaldo, J. B. Margolick, A. S. Fauci et al. 1997. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term non-progressors. J. Clin. Investig. 100:1581-1589.
6. Contopoulos-Ioannidis, D. G., T. R, O'Brien, J. J. Goedert, P. S. Rosenberg, and J. P. Ioannidis. 2003. Effect of CCR5-delta32 heterozygosity on the risk of perinatal HIV-1 infection: a meta-analysis. J. Acquir. Immune. Defic. Syndr. 32:70-76.
7. Dean, M., M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R. Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, E. Gomperts, S. Donfield, D. Vlahov, R. Kaslow, A. Saah, C. Rinaldo, R. Detels, S. J. O'Brien et al. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856-1862.
8. Goh, W. C., J. Markee, R. E. Akridge, M. Meldorf, L. Musey, T. Karchmer, M. Krone, A. Collier, L. Corey, M. Emerman, and M. J. McElrath. 1999. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J. Infect. Dis. 179:548-557.
9. Gonzalez, E., M. Bamshad, N. Sato, S. Mummidi, R. Dhanda, G. Catano, S. Cabrera, M. McBride, X. H. Cao, G. Merrill, P. O'Connell, D. W. Bowden, B. I. Freedman, S. A. Anderson, E. A. Walter, J. S. Evans, K. T. Stephan, R. A. Clark, S. Tyagi, S. S. Ahuja, M. J. Dolan, and S. K. Ahuja. 1999. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc. Natl. Acad. Sci. USA 96:12004-12009.
10. Gonzalez, E., R. Dhanda, M. Bamshad, S. Mummidi, R. Geevarghese, G. Catano, S. A. Anderson, E. A. Walter, K. T. Stephan, M. F. Hammer, A. Mangano, L. Sen, R. A. Clark, S. S. Ahuja, M. J. Dolan, and S. K. Ahuja. 2001. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc. Natl. Acad. Sci. USA 98:5199-5204.
11. Gonzalez, E., H. Kulkarni, H. Bolivar, A. Mangano, R. Sanchez, G. Catano, R. J. Nibbs, B. I. Freedman, M. P. Quinones, M. J. Bamshad, K. K. Murthy, B. H. Rovin, W. Bradley, R. A. Clark, S. A. Anderson, R. J. O'Connell, B. K. Agan, S. S. Ahuja, R. Bologna, L. Sen, M. J. Dolan, and S. K. Ahuja. 2005. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307:1434-1440.
12. Hladik, F., A. Desbien, J. Lang, L. Wang, Y. Ding, S. Holte, A. Wilson, Y. Xu, M. Moerbe, S. Schmechel, and M. J. McElrath. 2003. Most highly exposed seronegative men lack HIV-1-specific, IFN-gamma-secreting T cells. J. Immunol. 171:2671-2683.
13. Hoffman, T. L., R. R. MacGregor, H. Burger, R. Mick, R. W. Doms, and R. G. Collman. 1997. CCR5 genotypes in sexually active couples discordant for human immunodeficiency virus type 1 infection status. J. Infect. Dis. 176:1093-1096.
14. Huang, Y., W. A. Paxton, S. M. Wolinsky, A. U. Neumann, L. Zhang, T. He, S. Kang, D. Ceradini, Z. Jin, K. Yazdanbakhsh, K. Kunstman, D. Erickson, E. Dragon, N. R. Landau, J. Phair, D. D. Ho, and R. A. Koup. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2:1240-1243.
15. Humphreys, T. L., C. T. Schnizlein-Bick, B. P. Katz, L. A. Baldridge, A. F. Hood, R. A. Hromas, and S. M. Spinola. 2002. Evolution of the cutaneous immune response to experimental Haemophilus ducreyi infection and its relevance to HIV-1 acquisition. J. Immunol. 169:6316-6323.
16. Ioannidis, J. P., D. G. Contopoulos-Ioannidis, P. S. Rosenberg, J. J. Goedert, A. De Rossi, T. Espanol, L. Frenkel, M. J. Mayaux, M. L. Newell, S. G. Pahwa, C. Rousseau, G. Scarlatti, S. Sei, L. Sen, and T. R. O'Brien. 2003. Effects of CCR5-delta32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis. AIDS 17:1631-1638.
17. Ioannidis, J. P., P. S. Rosenberg, J. J. Goedert, L. J. Ashton, T. L. Benfield, S. P. Buchbinder, R. A. Coutinho, J. Eugen-Olsen, T. Gallart, T. L. Katzenstein, L. G. Kostrikis, H. Kuipers, L. G. Louie, S. A. Mallal, J. B. Margolick, O. P. Martinez, L. Meyer, N. L. Michael, E. Operskalski, G. Pantaleo, G. P. Rizzardi, H. Schuitemaker, H. W. Sheppard, G. J. Stewart, I. D. Theodorou, H. Ullum, E. Vicenzi, D. Vlahov, D. Wilkinson, C. Workman, J. F. Zagury, and T. R. O'Brien. 2001. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann. Intern. Med. 135:782-795.
18. Kawamura, T., F. O. Gulden, M. Sugaya, D. T. McNamara, D. L. Borris, M. M. Lederman, J. M. Orenstein, P. A. Zimmerman, and A. Blauvelt. 2003. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc. Natl. Acad. Sci. USA 100:8401-8406.
19. Khadir, A., F. Coutl'ee, P. Saint Antoine, C. Olivier, H. Voyer, and A. Kessous Elbaz. 1995. Clinical evaluation of Amplicor HIV-1 test for detection of human immunodeficiency virus type 1 proviral DNA in peripheral blood mononuclear cells. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 9:257-263.
20. Knudsen, T. B., T. B. Kristiansen, T. L. Katzenstein, and J. Eugen-Olsen. 2001. Adverse effect of the CCR5 promoter -2459A allele on HIV-1 disease progression. J. Med. Virol. 65:441-444.
21. Kostrikis, L. G., Y. Huang, J. P. Moore, S. M. Wolinsky, L. Zhang, Y. Guo, L. Deutsch, J. Phair, A. U. Neumann, and D. D. Ho. 1998. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat. Med. 4:350-353.
22. Kostrikis, L. G., A. U. Neumann, B. Thomson, B. T. Korber, P. McHardy, R. Karanicolas, L. Deutsch, Y. Huang, J. F. Lew, K. McIntosh, H. Pollack, W. Borkowsky, H. M. L. Spiegel, P. Palumbo, J. Oleske, A. Bardeguez, K. Luzuriaga, J. Sullivan, S. M. Wolinsky, R. A. Koup, D. D. Ho, and J. P. Moore. 1999. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J. Virol. 73:10264-10271.
23. Kristiansen, T. B., T. B. Knudsen, S. Ohlendorff, and J. Eugen-Olsen. 2001. A new multiplex PCR strategy for the simultaneous determination of four genetic polymorphisms affecting HIV-1 disease progression. J. Immunol. Methods 252:147-151.
24. Lin, Y. L., C. Mettling, P. Portales, J. Reynes, J. Clot, and P. Corbeau. 2002. Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc. Natl. Acad. Sci. USA 99:15590-15595.
25. Liu, H., Y. Hwangbo, S. Holte, J. Lee, C. Wang, N. Kaupp, H. Zhu, C. Celum, L. Corey, M. J. McElrath, and T. Zhu. 2004. Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. J. Infect. Dis. 190:1055-1058.
26. Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup, and N. R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377.
27. Louisirirotchanakul, S., H. Liu, A. Roongpisuthipong, E. E. Nakayama, Y. Takebe, T. Shioda, and C. Wasi. 2002. Genetic analysis of HIV-1 discordant couples in Thailand: association of CCR2 64I homozygosity with HIV-1-negative status. J. Acquir. Immune Defic. Syndr. 29:314-315.
28. Lucotte, G. 2002. Frequencies of 32 base pair deletion of the (Delta 32) allele of the CCR5 HIV-1 co-receptor gene in Caucasians: a comparative analysis. Infect. Genet. Evol. 1:201-205.
29. Mangano, A., E. Gonzalez, R. Dhanda, G. Catano, M. Bamshad, A. Bock, R. Duggirala, K. Williams, S. Mummidi, R. A. Clark, S. S. Ahuja, M. J. Dolan, R. Bologna, L. Sen, and S. K. Ahuja. 2001. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J. Infect. Dis. 183:1574-1585.
30. Mangano, A., J. Kopka, M. Batalla, R. Bologna, and L. Sen. 2000. Protective effect of CCR2-64I and not of CCR5-delta32 and SDF1-3′A in pediatric HIV-1 infection. S. Acquir. Immune. Defic. Syndr. 23:52-57.
31. Marmor, M., H. W. Sheppard, D. Donnell, S. Bozeman, C. Celum, S. Buchbinder, B. Koblin, and G. R. Seage III. 2001. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J. Acquir. Immune Defic. Syndr. 27:472-481.
32. Martin, H. L., Jr., P. M. Nyange, B. A. Richardson, L. Lavreys, K. Mandaliya, D. J. Jackson, J. O. Ndinya-Achola, and J. Kreiss. 1998. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J. Infect. Dis. 178:1053-1059.
33. Martin, M. P., M. Dean, M. W. Smith, C. Winkler, B. Gerrard, N. L. Michael, B. Lee, R. W. Doms, J. Margolick, S. Buchbinder, J. J. Goedert, T. R. O'Brien, M. W. Hilgartner, D. Vlahov, S. J. O'Brien, and M. Carrington. 1998. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282:1907-1911.
34. Martinson, J. J., N. H. Chapman, D. C. Rees, Y. T. Liu, and J. B. Clegg. 1997. Global distribution of the CCR5 gene 32-basepair deletion. Nat. Genet. 16:100-103.
35. McDermott, D. H., P. A. Zimmerman, F. Guignard, C. A. Kleeberger, S. F. Leitman, and P. M. Murphy. 1998. CCR5 promoter polymorphism and HIV-1 disease progression. Lancet 352:866-870.
36. Meyer, L., M. Magierowska, J. B. Hubert, C. Rouzioux, C. Deveau, F. Sanson, P. Debre, J. F. Delfraissy, I. Theodorou et al. 1997. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. AIDS 11:F73-F78.
37. Michael, N. L., G. Chang, L. G. Louie, J. R. Mascola, D. Dondero, D. L. Birx, and H. W. Sheppard. 1997. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat. Med. 3:338-340.
38. Mulherin, S. A., T. R. O'Brien, J. P. Ioannidis, J. J. Goedert, S. P. Buchbinder, R. A. Coutinho, B. D. Jamieson, L. Meyer, N. L. Michael, G. Pantaleo, G. P. Rizzardi, H. Schuitemaker, H. W. Sheppard, I. D. Theodorou, D. Vlahov, and P. S. Rosenberg. 2003. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS 17:377-387.
39. Mummidi, S., S. S. Ahuja, E. Gonzalez, S. A. Anderson, E. N. Santiago, K. T. Stephan, F. E. Craig, P. O'Connell, V. Tryon, R. A. Clark, M. J. Dolan, and S. K. Ahuja. 1998. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat. Med. 4:786-793.
40. Ometto, L., M. Zanchetta, A. Cabrelle, G. Esposito, M. Mainardi, L. Chieco-Bianchi, and A. De Rossi. 1999. Restriction of HIV type 1 infection in macrophages heterozygous for a deletion in the CC-chemokine receptor 5 gene. AIDS Res. Hum. Retrovir. 15:1441-1452.
41. Paxton, W. B., R. W. Coombs, M. J. McElrath, M. C. Keefer, J. Hughes, F. Sinangil, D. Chernoff, L. Demeter, B. Williams, L. Corey et al. 1997. Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. J. Infect. Dis. 175:247-254.
42. Plummer, F. A., J. N. Simonsen, D. W. Cameron, J. O. Ndinya-Achola, J. K. Kreiss, M. N. Gakinya, P. Waiyaki, M. Cheang, P. Piot, A. R. Ronald et al. 1991. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J. Infect. Dis. 163:233-239.
43. Quillent, C., E. Oberlin, J. Braun, D. Rousset, G. Gonzalez-Canali, P. Metais, L. Montagnier, J. L. Virelizier, F. Arenzana-Seisdedos, and A. Beretta. 1998. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 351:14-18.
44. Reeves, J. D., S. A. Gallo, N. Ahmad, J. L. Miamidian, P. E. Harvey, M. Sharron, S. Pohlmann, J. N. Sfakianos, C. A. Derdeyn, R. Blumenthal, E. Hunter, and R. W. Doms. 2002. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. USA 99:16249-16254.
45. Reynes, J., P. Portales, M. Segondy, V. Baillat, P. Andre, B. Reant, O. Avinens, G. Couderc, M. Benkirane, J. Clot, J. F. Eliaou, and P. Corbeau. 2000. CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J. Infect. Dis. 181:927-932.
46. Rowland-Jones, S. L., T. Dong, K. R. Fowke, J. Kimani, P. Krausa, H. Newell, T. Blanchard, K. Ariyoshi, J. Oyugi, E. Ngugi, J. Bwayo, K. S. MacDonald, A. J. McMichael, and F. A. Plummer. 1998. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Investig. 102:1758-1765.
47. Royce, R. A., A. Sena, W. Gates, Jr., and M. S. Cohen. 1997. Sexual transmission of HIV. N. Engl. J. Med. 336:1072-1078.
48. Salkowitz, J. R., S. E. Bruse, H. Meyerson, H. Valdez, D. E. Mosier, C. V. Harding, P. A. Zimmerman, and M. M. Lederman. 2003. CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin. Immunol. 108:234-240.
49. Samson, M., F. Libert, B. J. Doranz, J. Rucker, C. Liesnard, C. M. Farber, S. Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceille, G. Muyldermans, C. Verhofstede, G. Burtonboy, M. Georges, T. Imai, S. Rana, Y. Yi, R. J. Smyth, R. G. Collman, R. W. Doms, G. Vassart, and M. Parraentier. 1996. Resistance to HlV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725.
50. Schacker, T., A. C. Collier, J. Hughes, T. Shea, and L. Corey. 1996. Clinical and epidemiologic features of primary HIV infection. Ann. Intern. Med. 125:257-264.
51. Seage, G. R., III, S. E. Holte, D. Metzger, B. A. Koblin, M. Gross, C. Celum, M. Marmor, G. Woody, K. H. Mayer, C. Stevens, F. N. Judson, D. McKirnan, A. Sheon, S. Self, S. P. Buchbinder et al. 2001. Are US populations appropriate for trials of human immunodeficiency virus vaccine? Am. J. Epidemiol. 153:619-627.
52. Shieh, B., Y. E. Liau, P. S. Hsieh, Y. P. Yan, S. T. Wang, and C. Li. 2000. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int. Immunol. 12:1311-1318.
53. Smith, M. W., M. Dean, M. Carrington, C. Winkler, G. A. Huttley, D. A. Lomb, J. J. Goedert, T. R. O'Brien, L. P. Jacobson, R. Kaslow, S. Buchbinder, E. Vittinghoff, D. Vlahov, K. Hoots, M. W. Hilgartner, and S. J. O'Brien. 1997. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 277:959-965.
54. Tang, J., C. Rivers, E. Karita, C. Costello, S. Allen, P. N. Fultz, E. E. Schoenbaum, and R. A. Kaslow. 1999. Allelic variants of human beta-chemokine receptor 5 (CCR5) promoter: evolutionary relationships and predictable associations with HIV-1 disease progression. Genes Immun. 1:20-27.
55. Tang, J., B. Shelton, N. J. Makhatadze, Y. Zhang, M. Schaen, L. G. Louie, J. J. Goedert, E. C. Seaberg, J. B. Margolick, J. Mellors, and R. A. Kaslow. 2002. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J. Virol. 76:662-672.
56. Tuttle, D. L., J. K. Harrison, C. Anders, J. W. Sleasman, and M. M. Goodenow. 1998. Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J. Virol. 72:4962-4969.
57. Venkatesan, S., A. Petrovic, D. I. Van Ryk, M. Locati, D. Weissman, and P. M. Murphy. 2002. Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration. J. Biol. Chem. 277:2287-2301.
58. Vodicka, M. A., W. C. Gob, L. I. Wu, M. E. Rogel, S. R. Bartz, V. L. Schweickart, C. J. Raport, and M. Emerman. 1997. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 233:193-198.
59. Wu, L., G. LaRosa, N. Kassam, C. J. Gordon, H. Heath, N. Ruffing, H. Chen, J. Humblias, M. Samson, M. Parmentier, J. P. Moore, and C. R. Mackay. 1997. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186:1373-1381.
60. Wu, L., W. A. Paxton, N. Kassam, N. Ruffing, J. B. Rottman, N. Sullivan, H. Choe, J. Sodroski, W. Newman, R. A. Koup, and C. R. Mackay. 1997. CCR5 levels and expression patterns correlate with infectability by macrophage-tropic HIV-1 in vitro. J. Exp. Med. 185:1681-1691.
61. Zucker-Franklin, D., M. Fraig, and G. Grusky. 1995. Interaction of human immunodeficiency virus type 1, human T-cell leukemia/lymphoma virus type I (HTLV-I), and HTLV-II with in vitro-generated dendritic cells. Clin. Diagn. Lab. Immunol. 2:343-348.